List of TRB RepSeq datasets from Ref. [16].

Datasets are organized by patient and by antigens used for the in vitro stimulation of the patient’s PBMC. Neoantigens tested were chosen based on a measure of neoantigen “fitness” that accounts for: the neoantigen binding affinity to the patient’s MHC; its potential for being recognized by T cells, quantified by sequence similarity to infectious disease-related epitopes (“cross-reactive”), see [9, 16]. The neoantigens are generated by cancer-specific point mutations in antigens natural to the organism (“wild-type”). The green circle indicates neoantigens from the genetic locus MUC16, which were not selected based on neoantigen fitness.